Organisation paid for research Program year 2025 Source: CMS Open Payments

Chicago Ent Research LLC

Neither a doctor nor a teaching hospital

Research payments

$64,318

41 payments

Through program year 2025, Chicago Ent Research LLC is reported as receiving $64,318 in research payments, across 41 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $7,083 1
2024 Research $8,640 17
2023 Research $19,009 12
2022 Research $4,752 3
2020 Research $7,239 3
2019 Research $17,595 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biohaven Pharmaceutical Holding Company Ltd. $26,402 30 payments
  2. GlaxoSmithKline, LLC. $25,889 7 payments
  3. Eli Lilly and Company $7,083 1 payment
  4. OptiNose US, Inc. $2,750 1 payment
  5. Otonomy, Inc. $2,195 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 23 Doubleblind Randomized Placebocontrolled Safety and Efficacy Trial of Bhv3000 Rimegepant Orally Disintegrating Tablet Odt for the Acute Treatment of Chronic Rhinosinusitis CRS With Or Without Nasal Polyps $21,649 27 payments
  2. A Randomised Phiii Study to Assess the Effect of 100 MG SC Mepolizumab $19,889 5 payments
  3. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ Ly3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on A Background Therapy With Intranasal Corticosteroids $7,083 1 payment
  4. Realiti-N: A Multinational, Observational Study to Evaluate the Real-W $6,000 2 payments
  5. A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Chronic Rhinosinusitis (CRS)With or Without Nasal Polyps $4,752 3 payments
  6. A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day BID in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 $2,750 1 payment
  7. A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus $2,195 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record